Overview

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether fish oil supplementation with Lovaza, formally known as Omacor will result in a significant reduction in serum triglyceride (TG), an increase in high density lipoproteins(HDL), and an improvement of endothelial dysfunction.
Phase:
Phase 4
Details
Lead Sponsor:
Todd Conley
Tufts University